$SYBX News

Last published 1y ago

1y agoSYBXSynlogic Reports Third Quarter 2024 Financial ResultsGlobeNewswireWINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results
2y agoSYBXSynlogic Reports Second Quarter 2024 Financial ResultsGlobeNewswireWINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results
2y agoSYBXSynlogic Reports First Quarter 2024 Financial ResultsGlobeNewswireCAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for
2y agoLCTX SYBX VIRLineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate DevelopmentBusiness WireLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry
2y agoSYBXSynlogic Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswireCAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results
2y agoSYBXSynlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate UpdateGlobeNewswireDecision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe and well-tolerated Board of Directors plans to perform assessment
2y agoSYBXSynlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical HomocystinuriaGlobeNewswireFindings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study SYNB1353 was
2y agoSYBXSynlogic Provides Corporate Update and Outlook for 2024GlobeNewswire- Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age - - Top-line, Phase 3 data in PKU expected in H1 2025 - CAMBRIDGE,
2y agoSYBXSynlogic Announces Contract with the Air Force Research LabGlobeNewswireCAMBRIDGE, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious
2y agoSYBXSynlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023GlobeNewswire- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation - CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic,
2y agoACU CURO CWD ISSC+12Sidoti Events, LLC's Virtual November Micro-Cap ConferenceACCESS NewswireNEW YORK, NY / ACCESSWIRE / November 14, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking
3y agoSYBXSynlogic Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswire- Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 - - Progress of the Synpheny-3 pivotal trial in phenylketonuria
3y agoSYBXSynlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche CollaborationGlobeNewswireCAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious
3y agoSYBXSynlogic Announces Closing of $21.0 Million Underwritten Public OfferingGlobeNewswireCAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious
3y agoSYBXSynlogic Announces Pricing of $21.0 Million Underwritten Public OfferingGlobeNewswireCAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of
3y agoSYBXSynlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature MetabolismGlobeNewswireCAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of
3y agoSYBXSynlogic Announces Reverse Stock SplitGlobeNewswireCAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of
3y agoSYBXSynlogic to Participate in Chardan's Genetic Medicines ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of
3y agoSYBXSynlogic Announces CEO Aoife Brennan Named to PharmaVoice 100GlobeNewswireCAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of
3y agoSYBXSynlogic Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireCAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious
3y agoSNCE SYBXSynlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., July 11, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the clinical research industry-leading Metasite™ has been chosen by Synlogic, (NASDAQ:SYBX), a
3y agoSYBXSynlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of PhenylketonuriaGlobeNewswireCAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious
3y agoSYBXSynlogic Announces International Nonproprietary Name Selection for SYNB1934GlobeNewswireThe World Health Organization has approved "labafenogene marselecobac" Name attributes recognize Synlogic's proprietary technology and commitment to phenylketonuria community CAMBRIDGE, Mass., June 28, 2023 (GLOBE
3y agoSYBXSynlogic Announces Participation in SVB Securities Healthcare Therapeutics ForumGlobeNewswireCAMBRIDGE, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious
3y agoSYBXSynlogic Reminds Stockholders of 2023 Annual General Meeting DetailsGlobeNewswireCAMBRIDGE, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), the leading company advancing therapeutics based on synthetic biology, today reminded stockholders that it will hold its 2023 Annual
3y agoSYBXSynlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of PhenylketonuriaGlobeNewswireRegistrational study designed to support BLA submission of first-in-class biotherapeutic Company further streamlining organization to focus resources on execution of late clinical-stage programs in rare metabolic
3y agoSYBXSynlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) ConferenceGlobeNewswireCAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), the leading company advancing therapeutics based on synthetic biology, today announced its planned presentations at the 2023 Synthetic
3y agoSYBXSynlogic to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B. Ch.B., President and
3y agoSYBXSynlogic Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswire- Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – - Recent milestones include receipt of Rare Pediatric and Orphan Drug Designations from the FDA, and orphan designation from
3y agoSYBXSynlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of PhenylketonuriaGlobeNewswireCAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA)
3y agoSYBXSynlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate UpdatesGlobeNewswire– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU) – - Platform
3y agoSYBXSynlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of PhenylketonuriaGlobeNewswireCAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines Agency (EMA) issued
3y agoSYBXSynlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual MeetingGlobeNewswireCAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the company's Phase 2
3y agoSYBXEfficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3) - NCT05764239ClinicalTrials.govTo assess the percentage change in blood phenylalanine (Phe) level, To evaluate efficacy of SYNB1934 versus placebo in the responder population through the change from baseline to Week 4 in blood Phe level., To assess the absolute change in Phe level, (and 4 more...)
3y agoSYBXSynlogic to Present at the Oppenheimer 33rd Annual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B. Ch.B., Synlogic
3y agoSYBXSynlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual MeetingGlobeNewswire– Podium presentation on Phase 2 phenylketonuria (PKU) data – – Poster presentations on Phase 1 homocystinuria (HCU) data and HCU preclinical data – CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc.
3y agoSYBXSynlogic Announces Participation in Upcoming Investor and Industry ConferencesGlobeNewswireCAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), the leading company advancing therapeutics based on synthetic biology, today announced it will participate in the following upcoming
3y agoSYBXSynlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)GlobeNewswireCAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that SYNB1934 was granted Rare Pediatric Disease
3y agoSYBXSynlogic Provides Corporate Update and Outlook for 2023GlobeNewswirePivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023 Rare Pediatric Disease Designation received for SYNB1353 for homocystinuria (HCU) Cash runway expected into H2 2024 CAMBRIDGE, Mass., Jan.
3y agoSYBXSynlogic Announces Appointment of Dr. Dave Hava as Head of Research and DevelopmentGlobeNewswireCAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary
3y agoSYBXSynlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b StudyGlobeNewswireResults include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients Favorable safety and tolerability, with frequency and severity of adverse events similar across placebo and
3y agoSYBXSynlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business UpdateGlobeNewswireTop-line Phase 1 data in healthy volunteers show that SYNB1353 reduces plasma methionine by consuming methionine in the GI tract SYNB1353 has been granted Orphan Drug Designation (ODD) from the FDA for the treatment of
4y agoSYBXSynlogic Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireTop-line Phase 2 data for phenylketonuria (PKU) demonstrated robust plasma Phe reduction and high response rate; Phase 3 study initiation planned for H1 2023 Clinical readouts for SYNB1353 for homocystinuria (HCU) and
4y agoSYBXSynlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3GlobeNewswirePositive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of activity across all
4y agoSYBXSynlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel DiseaseGlobeNewswireCAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today that it has received a milestone payment for the achieve
4y agoSYBXSynlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)GlobeNewswireCAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announce
4y agoDNA SYBXSynlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo BioworksPR NewswireSYNB2081 is the second clinical drug candidate developed through the partnership between Ginkgo and Synlogic CAMBRIDGE, Mass. and BOSTON, Aug. 11, 2022 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medi
4y agoSYBXSynlogic Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswire– Three clinical data readouts across three programs expected in H2 2022 – – PKU Phase 3 readiness activities underway for planned start in H1 2023 – – $106.8 million in cash, cash equivalents and short-term investments support projecte
4y agoSYBXSynlogic Announces Second Quarter 2022 Conference Call and WebcastGlobeNewswireCAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announc
4y agoSYBXSafety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers - NCT05462132ClinicalTrials.govNumber of participants with abnormal laboratory values and/or adverse events, The rate at which the SYNB1353 strain clears